H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Veru to $21 from $24 and keeps a Buy rating on the shares after an FDA advisory committee voted 8 no and 5 yes for sabizabulin’s Emergency Use Application. The analyst believes the FDA may deny the company’s EUA application and request additional clinical data.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VERU:
- Veru put volume heavy and directionally bearish
- American Association for Cancer Research to hold a symposium
- Veru announces late-breaker oral presentation of sabizabulin treatment
- Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
- Veru call volume above normal and directionally bullish
Questions or Comments about the article? Write to editor@tipranks.com